Interleukin-6 and Diabetic Retinopathy: A Systematic Review and Meta-Analysis

References

• Abdulsalam S, Ibrahim A, Saidu H, Muazu M, Aliyu UT, Umar HI, Gezawa ID, Owolabi LF. Knowledge, attitude, and practice of diabetic retinopathy among physicians in Northwestern Nigeria. Niger J Clin Pract. 2018;21(4):478–83. doi:10.4103/njcp.njcp_266_17.
   PubMed Web of Science ®Google Scholar
• Li YY, Yang XF, Gu H, Senllingen T, Liu XP, Liu NP. The relationship between insulin resistance/β-cell dysfunction and diabetic retinopathy in Chinese patients with type 2 diabetes mellitus: the Desheng Diabetic Eye Study. Int J Ophthalmol. 2018;11(3):493–500. doi:10.18240/ijo.2018.03.21.
   PubMed Web of Science ®Google Scholar
• Karam T, Kamath YS, Rao LG, Rao KA, Shenoy SB, Bhandary SV. Diabetic retinopathy in patients with diabetic foot syndrome in South India. Indian J Ophthalmol. 2018;66(4):547–50. doi:10.4103/ijo.IJO_1000_17.
   PubMed Web of Science ®Google Scholar
• Tsai T, Kuehn S, Tsiampalis N, Vu MK, Kakkassery V, Stute G, Dick HB, Joachim SC. Anti-inflammatory cytokine and angiogenic factors levels in vitreous samples of diabetic retinopathy patients. PLoS One. 2018;13(3):e0194603. doi:10.1371/journal.pone.0194603.
   PubMed Web of Science ®Google Scholar
• Dumitrescu AG, Istrate SL, Labcu RC, Guta OM, Ciuluvica R, Voinea L. Retinal changes in diabetic patients without diabetic retinopathy. Rom J Ophthalmol. 2017;61:249–55.
   PubMedGoogle Scholar
• Makwana T, Takkar B, Venkatesh P, Sharma JB, Gupta Y, Chawla R, Vohra R, Kriplani A, Tandon N. Prevalence, progression, and outcomes of diabetic retinopathy during pregnancy in Indian scenario. Indian J Ophthalmol. 2018;66(4):541–46. doi:10.4103/ijo.IJO_1062_17.
   PubMed Web of Science ®Google Scholar
• Sturrock BA, Rees G, Lamoureux EL, Wong TY, Holloway E, Fenwich EK. Individuals’ perspectives on coping with vision loss from diabetic retinopathy. Optom Vis Sci. 2018;95(4):362–72. doi:10.1097/OPX.0000000000001209.
   PubMed Web of Science ®Google Scholar
• Zhang W, Chen S, Liu ML. Pathogenic roles of microvesicles in diabetic retinopathy. Acta Pharmacol Sin. 2018 Jan;39(1):1–11. doi:10.1038/aps.2017.77.
   PubMed Web of Science ®Google Scholar
• Liu L, Zuo Z, Lu S, Liu A, Liu X. Naringin attenuates diabetic retinopathy by inhibiting inflammation, oxidative stress and NF-κB activation in vivo and in vitro. Iran J Basic Med Sci. 2017;20(7):813–21. doi:10.22038/IJBMS.2017.9017.
   PubMed Web of Science ®Google Scholar
• Rubsam A, Parikh S, Fort PE. Role of inflammation in diabetic retinopathy. Int J Mol Sci. 2018;19(4):e 924. doi:10.3390/ijms19040942.
   Web of Science ®Google Scholar
• Krick TW, Bressler NM. Recent clinically relevant highlights from the diabetic retinopathy clinical research network. Curr Opin Ophthalmol. 2018;29(3):199–205. doi:10.1097/ICU.0000000000000472.
   PubMed Web of Science ®Google Scholar
• Chandra S, Sheth J, Anantharaman G, Gopalakrishnan M. Ranibizumab-induced retinal reperfusion and regression of neovascularization in diabetic retinopathy: an angiographic illustration. Am J Ophthalmol Case Rep. 2018;9:41–44. doi:10.1016/j.ajoc.2018.01.006.
   PubMedGoogle Scholar
• Arutyunov GP, Dragunov DO, Sokolova AV, Mitrokhin VM, Kamkin AG, Latyshev TV. Factors associated with levels of interleukins −18, −8, and −6 in hypertensive patients at high and very high cardiovascular risk. Kardiologiia. 2017;57:69–75.
   PubMed Web of Science ®Google Scholar
• Yu Y, Zhang J, Zhu R, Zhao R, Chen J, Jin J, Tian Y, Su SB. The profile of angiogenic factors in vitreous humor of the patients with proliferative diabetic retinopathy. Curr Mol Med. 2017;17(4):280–86. doi:10.2174/1566524017666171106111440.
   PubMed Web of Science ®Google Scholar
• Noma H, Mimura T, Yasuda K, Motohashi R, Kotake O, Shimura M. Aqueous humor levels of soluble vascular endothelial growth factor receptor and inflammatory factors in diabetic macular edema. Ophthalmologica. 2017;238(1–2):81–88. doi:10.1159/000475603.
   PubMed Web of Science ®Google Scholar
• Yoshimura T, Sonoda KH, Sugahara M, Mochizuki Y, Enaida H, Oshima Y, Ueno A, Hata Y, Yoshida H, Ishibashi T. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One. 2009;4(12):e8158. doi:10.1371/journal.pone.0008158.
   PubMed Web of Science ®Google Scholar
• Mocan MC, Kadayifcilar S, Eldem B. Elevated intravitreal interleukin-6 levels in patients with proliferative diabetic retinopathy. Can J Ophthalmol. 2006;41(6):747–52. doi:10.3129/i06-070.
   PubMed Web of Science ®Google Scholar
• Chen H, Wen F, Zhang XZ, Su SB. Expression of T-helper-associated cytokines in patients with type 2 diabetes mellitus with retinopathy. Mol Vis. 2012;18:219–26.
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee W, Kwon OH, Kim JH, Kwon OW, Kim KH, Lim JB. Cytokine profile of peripheral blood in type 2 diabetes mellitus patients with diabetic retinopathy. Ann Clin Lab Sci. 2008;38:361–67.
   PubMed Web of Science ®Google Scholar
• Joanna AM, JoIanta OM. Assessment of selected adhesion molecule and proinflammatory cytokine levels in the vitreous body of patients with type 2 diabetes — role of the inflammatory–immune process in the pathogenesis of proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2008 Dec;246(12):1665–70. doi:10.1007/s00417-008-0868-6.
   PubMed Web of Science ®Google Scholar
• Afzal N, Zaman S, Shahzad F, Javaid K, Zafar A, Nagi AH. Immune mechanisms in type-2 diabetic retinopathy. J Pak Med Assoc. 2015;65:159–63.
   PubMed Web of Science ®Google Scholar
• Boss JD, Signgh PK, Pandya HK, Tosi J, Kim C, Tewari A, Juzych MS, Abrams GW, Kumar A. Assessment of neurotrophins and inflammatory mediators in vitreous of patients with diabetic retinopathy. Invest Ophthalmol Vis Sci. 2017;58(12):5594–603. doi:10.1167/iovs.17-21973.
   PubMed Web of Science ®Google Scholar
• Canataroglu H, Varinli I, Ozacn AA, Canataroglu A, Doran F, Varinli S. Interleukin (IL)-6, Interleukin (IL)-8 levels and cellular composition of the vitreous humor in proliferative diabetic retinopathy, proliferative vitreoretinopathy, and traumatic proliferative vitreoretinopathy. Ocul Immunol Inflamm. 2005;13:375–81.
   PubMed Web of Science ®Google Scholar
• Chen H, Wen F, Zhang X, Su SB. Expression of T-helper-associated cytokines in patients with type 2 diabetes mellitus with retinopathy. Mol Vis. 2012;18:219–26.
   PubMed Web of Science ®Google Scholar
• Chen H, Zhang X, Liao N, Wen F. Assessment of biomarkers using multiplex assays in aqueous humor of patients with diabetic retinopathy. BCM Opthalmol. 2017;17(1):176–85. doi:10.1186/s12886-017-0572-6.
   PubMed Web of Science ®Google Scholar
• Chernykh VV, Varvarinsky EV, Smirnov EV, Chernykh DV, Trunov AN. Proliferative and inflammatory factors in the vitreous of patients with proliferative diabetic retinopathy. Indian J Ophthalmol. 2015;63(1):33–36. doi:10.4103/0301-4738.151464.
   PubMed Web of Science ®Google Scholar
• Gustavsson C, Agardh CD, Agardh E. Profile of intraocular tumour necrosis factor-a and interleukin-6 in diabetic subjects with different degrees of diabetic retinopathy. Ata Ophthalmol. 2013;91:445–52. doi:10.1111/j.1755-3768.2012.02430.x.
   PubMed Web of Science ®Google Scholar
• Kawashima M, Shoji J, Masami Nakajima M, Kamura Y, Sato Y. Soluble IL-6 receptor in vitreous fluid of patients with proliferative diabetic retinopathy. Jpn J Ophthalmpl. 2007;51(2):100–04. doi:10.1007/s10384-006-0411-4.
   PubMed Web of Science ®Google Scholar
• Koleva-Georgieva DN, Sivkova NP, Terzieva D. Serum inflammatory cytokings IL-1β, IL-6, TNF-a and VEGF have influence on the development of diabetic retinopathy. Folia Med. 2011;53:44–50.
   Google Scholar
• Koskela UE, Kuusisto SM, Nissinen AE, Savolainen AE, Liinamaa MJ. High Vitreous Concentration of IL-6 and IL-8, but not of adhesion molecules in relation to plasma concentrations in proliferative diabeticretinopathy. Ophthalmic Res. 2013;49(2):108–14. doi:10.1159/000342977.
   PubMed Web of Science ®Google Scholar
• Loukovaara S, Piippo N, Kinnunen K, Hytti M, Kaarniranta K, Kauppinen A. NLRP3 inflammasome activation is associated with proliferative diabetic retinopathy. Acta Ophthalmol. 2017 Dec;95(8):803–08. doi:10.1111/aos.13427.
   PubMed Web of Science ®Google Scholar
• Hernandez-Da Mota SE, Soto-Bahena JJ, Viveros-Sandoval ME. Cardiel-Rios. Pro-inflammatory serum cytokines in diabetic retinopathy. Cir Cir. 2015;83(2):100–06. doi:10.1016/j.circir.2015.04.003.
   PubMed Web of Science ®Google Scholar
• Mysliwiec M, Balcerska A, Zorena K, Mysliwska J, Lipowski P, Raczynska K. The role of vasclular endothelial factor alpha and interleukin-6 in pathogenesis of diabetic retinopathy. Diabetes Res Clin Pract. 2008;79(1):141–46. doi:10.1016/j.diabres.2007.07.011.
   PubMed Web of Science ®Google Scholar
• Nakamura N, Hasegawa G, Obayashi H, Yamazaki M, Ogata M, Nakano K, Yoshikawa T, Watanabe A, Kinoshita S, Fujianami A. Increased concentration of pentosidine, an advanced glycation end product, and interleukin-6 in the vitreous of patients with proliferative diabetic retinopathy. Diabetes Res Clin Pract. 2003;61:93–101.
   PubMed Web of Science ®Google Scholar
• Oh IK, Kim SW, Oh J, Lee TS, Hua H. Inflammatory and angiogenic factors in the aqueous humor and the relationship to diabetic retinopathy. Cur Eye Res. 2010;35(12):1116–27. doi:10.3109/02713683.2010.510257.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Nakazawa M, Suzuki K, Yamazaki H, Miyagawa Y. Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion. Jpn J Ophthalmol. 2011;55(3):256–63. doi:10.1007/s10384-011-0004-8.
   PubMed Web of Science ®Google Scholar
• Tasci E, Ozbek MN, Onenli-Mungan N, Temiz F, Topaloglu AK, Yuksel B. Low serum adiponectin levels in children and adolescents with diabetic retinopathy. Eurasian J Med. 2011;43(1):18–22. doi:10.5152/eajm.2011.04.
   PubMedGoogle Scholar
• Yi X, Sun J, Li L, Wei Q, Qian Y, Chen X, Ma L. Research communication 1,25-Dihydroxyvi- tamin D3 deficiency is involved in the pathogenesis of diabetic retinopathy in the uygur population of China. IUBMB Life. 2016;68(6):445–51. doi:10.1002/iub.1501.
   PubMed Web of Science ®Google Scholar
• Yoshida S, Kubo Y, Kobayashi Y, Zhou Y, Nakama T, Yamaguchi M, Tachibana T, Ishikawa K, Arita R, Nakao S, et al. Increased vitreous concentrations of MCP-1 and IL-6 after vitrectomy in patients with proliferative diabetic retinopathy: possible association with postoperative macular oedema. Br J Ophthalmol. 2015;99(7):960–66. doi:10.1136/bjophthalmol-2014-306366.
   PubMed Web of Science ®Google Scholar
• Yuuki T, Kanda T, Kimura Y, Kootajima N, Tamura J, Kobayashi I, Kishi S. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complications. 2001;15:257–59.
   PubMed Web of Science ®Google Scholar
• Tsai T, Kuehn S, Tsiampalis N, Vu MK, Kakkassery V, Stute G, Dick HB, Joachim SC. etAnti-inflammatory cytokine and angiogenic factors levels in vitreous samples of diabetic retinopathy patients. PLoS One. 2018;27(3):e0194603. doi:10.1371/journal.pone.0194603.
   Web of Science ®Google Scholar
• Funatsu H, Yamashita H, Shimizu E, Kojima R, Hori S. Relationship between vascular endothelial growth factor and interleukin-6 in diabetic retinopathy. Retina. 2001;21:469–77.
   PubMed Web of Science ®Google Scholar
• Kaviarasan K, Jithu M, Arif Mull M, Sharma T, Sivasankar S, Das UN, Angayarkanni N. Low blood and vitreal BDNF, LXA4 and altered Th1/Th2 cytokine balance are potential risk factors for diabetic retinopathy. Metabolism. 2015;64(9):958–66. doi:10.1016/j.metabol.2015.04.005.
   PubMed Web of Science ®Google Scholar
• Ma Y, Tao Y, Lu Q, Jiang YR. Intraocular expression of serum amyloid A and Interleukin-6 in proliferative diabetic retinopathy. Am J Ophthalmol. 2011;152(4):678–85. doi:10.1016/j.ajo.2011.03.007.
   PubMed Web of Science ®Google Scholar
• Scboenberher SD, Kim SJ, Sheng J, Rezaei KA, Lalezary M, Cherney E. Increased Prostaglandin E2 (PGE2) Levels in proliferativediabetic retinopathy, and correlation with VEGF and inflammatory cytokines. Invest Ophthalmol Vis Sci. 2012;53(9):5906–11. doi:10.1167/iovs.12-10410.
   PubMed Web of Science ®Google Scholar
• Xu Y, Cheng Q, Yang B, Yu S, Xu F, Lu L, Liang X. Increased sCD200 levels in vitreous of patients with proliferative diabetic retinopathy and its correlation with VEGF and proinflammatory cytokines. Invest Ophthalmol Vis Sci. 2015;56(11):6564–72. doi:10.1167/iovs.15-16854.
   Web of Science ®Google Scholar
• Zou HL, Wang Y, Gang Q, Zhang Y, Sun Y. Plasma level of miR-93 is associated with higher risk to develop type 2 diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2017;255(6):1159–66. doi:10.1007/s00417-017-3638-5.
   PubMed Web of Science ®Google Scholar
• Hendrick AM, Gibson MV, Kulshreshtha A. Diabetic Retinopathy. Prim Care. 2015;42(3):451–64. doi:10.1016/j.pop.2015.05.005.
   PubMed Web of Science ®Google Scholar
• Ghaffar T, Marwat ZI, Ullah F, Khan S, Hassan Aamir AU. Association of serum total bilirubin level with diabetic retinopathy in type 2 diabetes mellitus. J Ayub Med Coll. 2016;28:537–41.
   PubMedGoogle Scholar
• Barliya T, Dardik R, Nisqav Y, Dachbash M, Gaton D, Kenet G, Ehrlich R, Weinberger D, Libnat T. Possible involvement of NETosis in inflammatory processes in the eye: evidence from a small cohort of patients. Mol Vis. 2017;23:922–32.
   PubMed Web of Science ®Google Scholar
• Miller K, Fortun JA. Diabetic macular edema: current understanding, pharmacologic treatment options, and developing therapies. Asia Pac J Ophthalmol (Phila). 2018;7(1):28–35. doi:10.22608/APO.2017529.
   PubMed Web of Science ®Google Scholar
• Qiu AW, Bian Z, Mao PA, Liu QH. IL-17A exacerbates diabetic retinopathy by impairing Müller cell function via Act1 signaling. Exp Mol Med. 2016;16;48:e280.
   Web of Science ®Google Scholar
• Chen H, Zhang X, Liao N, Mi L, Peng Y, Liu B, Zhang S, Wen F. Enhanced expression of NLRP3 inflammasome-related inflammation in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2018;59(2):978–85. doi:10.1167/iovs.17-22816.
   PubMed Web of Science ®Google Scholar
• Zorena K, Mysliwska J, Mysliwiec M, Balcerska A, Hak L, Lipowski P, Raczynska K. Serum TNF-Alpha level predicts nonproliferative diabetic retinopathy in children. Mediators Inflamm. 2007;2007:92196. doi:10.1155/2007/92196.
   PubMed Web of Science ®Google Scholar
• Yuuki T, Kanda T, Kimura Y, Kotajima N, Tamura J, Kobayashi I, Kishi S. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complications. 2001;15:257–59.
   PubMed Web of Science ®Google Scholar
• Nakamura S, Iwasaki N, Funatsu H, Kitano S, Iwamoto Y. Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2009;247(1):21–26. doi:10.1007/s00417-008-0915-3.
   PubMed Web of Science ®Google Scholar
• Sen A, Paine SK, Chowdhury IH, Mukherjee A, Choudhuri S, Saha A, Mandal LK, Bhattacharya B. Impact of interleukin-6 promoter polymorphis and serum interleukin-6 level on the acute inflammation and neovascularization stages of patients with Eales’ disease. Mol Vis. 2011;17:2552–63.
   PubMed Web of Science ®Google Scholar
• Aguilera E, Serra-Planas E, Granada ML, Pellitero S, Reverter J, Alonso N, Soldevila B, Mauricio D, Puig-Domingo M. Relationship of YKL-40 and adiponectin and subclinical atherosclerosis in asymptomatic patients with type 1 diabetes mellitus from a European Mediterranean population. Cardiovasc Diabetol. 2015;14:121. doi:10.1186/s12933-015-0287-z.
   PubMed Web of Science ®Google Scholar
• Yi X, Sun J, Li L, Wei Q, Qian Y, Chen X, Ma L. 1,25-Dihydroxyvitamin D3 deficiency is involved in the pathogenesis of diabetic retinopathy in the uygur population of China. IUBMB Life. 2016;68(6):445–51. doi:10.1002/iub.1501.
   PubMed Web of Science ®Google Scholar